ライフサイエンスコーパス: thrombopoietin

1 nced reactive myeloproliferative response to thrombopoietin.

2 n, soluble transferrin receptor (sCD71), and thrombopoietin.

3 pon stimulation of primary megakaryocytes by thrombopoietin.

4 es, and show altered biochemical response to thrombopoietin.

5 an CD34(+) cells cultured in the presence of thrombopoietin.

6 duction by a similar mechanism to endogenous thrombopoietin.

7 reduced levels of plasma erythropoietin and thrombopoietin.

8 cktail of stem cell factor, flt3 ligand, and thrombopoietin.

9 ured in the presence of stem cell factor and thrombopoietin.

10 ption factor scl and c-mpl, the receptor for thrombopoietin.

11 unction, and raised serum erythropoietin and thrombopoietin.

12 -6, stem cell factor (SCF), Flt3 ligand, and thrombopoietin.

13 cting cytokines kit ligand, flt3 ligand, and thrombopoietin.

14 two doses of 1.2 microg/kg recombinant human thrombopoietin.

15 feration of BaF3/Mpl cells in the absence of thrombopoietin.

16 and controls the proliferative responses to thrombopoietin.

17 tem-cell-derived hematopoietic cultures with thrombopoietin, a multistage cytokine.

18 Thrombopoietin affects nearly all aspects of platelet pr

19 ecular and cellular mechanisms through which thrombopoietin affects platelet production provide new i

20 BEST PRACTICE ADVICE 5: Thrombopoietin agonists are a good alternative to platel

21 prove response rates, as recently shown with thrombopoietin analogs.

22 lear cells were incubated in the presence of thrombopoietin and 10% plasma from either ITP patients (

23 Thrombopoietin and basic fibroblast growth factor are id

24 egulation occurs with the receptors for Epo, thrombopoietin and growth hormone but not with the recep

25 e potential of hemopoietic growth factors (, thrombopoietin and interleukin-11) to prevent or treat n

26 Silencing thrombopoietin and interleukin-6 abrogated thrombocytosi

27 Plasma levels of thrombopoietin and interleukin-6 were significantly elev

28 Thrombopoietin and its receptor (Mpl) support survival a

29 development of antibodies against endogenous thrombopoietin and subsequent refractory thrombocytopeni

30 gulate the expression of genes such as THPO (thrombopoietin) and ATP5B (ATP synthase, H+ transporting

31 x were reduced, while reticulated platelets, thrombopoietin, and bone marrow megakaryocyte colony-for

32 r angiogenic growth factors (angiopoietin-2, thrombopoietin, and epidermal growth factor).

33 ure containing IL-3, IL-6, stem cell factor, thrombopoietin, and Flt3 ligand induced Ccn3/Nov mRNA ov

34 ng STAT5 phosphorylation in response to IL3, thrombopoietin, and GM-CSF.

35 Because the erythropoietin, thrombopoietin, and granulocyte colony-stimulating facto

36 topoietic cell receptors for erythropoietin, thrombopoietin, and granulocyte colony-stimulating facto

37 ter exhibited reduced proplatelet formation, thrombopoietin, and integrin signaling.

38 tly of the key regulator of megakaryopoiesis thrombopoietin, and may occur during situations of acute

39 h the recent cloning and characterization of thrombopoietin, appreciation of the molecular events sur

40 being given a new spin, newer agents such as thrombopoietins are showing significant promise.

41 ifferentiation process driven by the hormone thrombopoietin by which haematopoietic progenitor cells

42 ic progenitor cells, during pre-expansion by thrombopoietin, c-kit ligand, and FLT-3 ligand, on recom

43 ved platelets derived from recombinant human thrombopoietin can provide a viable strategy to minimise

44 We identify roles for thrombopoietin, CCL3, and direct cell-cell interactions

45 platelet and red blood cell variability, and thrombopoietin/cellular myeloproliferative leukemia viru

46 s harvested from healthy donors treated with thrombopoietin could provide larger increases in platele

47 yocytes may reduce metastasis, we found that thrombopoietin-deficient mice exhibited a 90% relative d

48 imulated hematopoiesis both in wild-type and thrombopoietin-deficient mice.

49 rapidly overgrown by a unique population of thrombopoietin-dependent blasts that express immature ma

50 NK mutants displayed augmented and sustained thrombopoietin-dependent growth and signaling.

51 Transfusion of thrombopoietin-derived autologous platelets might provid

52 ssful search to purify and molecularly clone thrombopoietin did not begin until the oncogene v-mpl wa

53 Strikingly, thrombopoietin-differentiated DAMI cells, which represen

54 ation of transforming growth factor-beta1 in thrombopoietin-driven experimental myelofibrosis in mice

55 response to stem cell factor and diminished thrombopoietin-evoked Erk activation.

56 Recombinant human thrombopoietin facilitated collection of multiple units

57 here that the 2 cytokines interleukin 3 and thrombopoietin have the ability to expand hematopoietic

58 ve reduced activation of Rap1 in response to thrombopoietin, IGF-1,ADP, SFLLRN, and thrombin.

59 ys with OP9 stromal cells in the presence of thrombopoietin, IL-6, and IL-11 resulted in the developm

60 The levels of thrombopoietin, immature platelet fraction, and mean pla

61 rmined by quantification of platelet counts, thrombopoietin, immature platelet fraction, and mean pla

62 utants and platelets from patients displayed thrombopoietin-independent phosphorylation of signal tra

63 R-34a expression is also up-regulated during thrombopoietin-induced differentiation of CD34(+) hemato

64 ispensable for megakaryocytopoiesis, and for thrombopoietin-induced ERK1/2 activation in primary mega

65 y increase in A-Raf or B-Raf expression, and thrombopoietin-induced ERK1/2 phosphorylation is similar

66 theless, the absence of Raf-1 does not alter thrombopoietin-induced expansion of primary megakaryocyt

67 from human haematopoietic progenitor cells, thrombopoietin-induced megakaryocytic differentiation le

68 f significant stromal fibrosis in a model of thrombopoietin-induced myelofibrosis.

69 tors for IL-2 (JAK1- and JAK3-dependent) and thrombopoietin (JAK2-dependent), demonstrating the high

70 tact with hECs and minimal concentrations of thrombopoietin/Kit-ligand/Flt3-ligand resulted in a 400-

71 Plasma thrombopoietin levels inversely correlated with platelet

72 Serum thrombopoietin levels overlapped in mutant vs control mi

73 yrosine kinase JAK2 and elevated circulating thrombopoietin levels.

74 Thrombopoietin may increase the number of hematopoietic

75 An observed increase in thrombopoietin-mediated Akt phosphorylation in the trunc

76 illustrate an involvement for GP Ibalpha in thrombopoietin-mediated events of megakaryocyte prolifer

77 tients, resulting in diminished thrombin and thrombopoietin-mediated integrin alpha(IIb)beta(3) activ

78 In addition, thrombopoietin-mediated JAK2 phosphorylation was unchang

79 a/14-3-3xi/PI-3 kinase complex in regulating thrombopoietin-mediated responses.

80 unosuppression to determine whether the oral thrombopoietin mimetic eltrombopag (Promacta) can improv

81 ponse may also occur with alemtuzumab or the thrombopoietin mimetic eltrombopag in refractory AA.

82 hGH enhances the effect of a tandem dimer of thrombopoietin mimetic peptide (dTMP) on thrombopoiesis,

83 ed the efficacy and safety of romiplostim, a thrombopoietin mimetic, in patients with low- or interme

84 Romiplostim, a thrombopoietin mimetic, increases platelet counts in pat

85 Eltrombopag belongs to a new class of thrombopoietin-mimetic drugs that raise platelet counts

86 Romiplostim, a thrombopoietin-mimetic peptibody, increases and maintain

87 ated by the therapeutic effectiveness of the thrombopoietin mimetics in ITP.

88 te-macrophage colony-stimulating factor, and thrombopoietin); most have proinflammatory effects.

89 tly reported increased in vivo activities of thrombopoietin (Mpl ligand) and leptin following carbohy

90 cluding receptors for erythropoietin (EPOR), thrombopoietin (MPL), and granulocyte colony-stimulating

91 cture a small upstream open reading frame in thrombopoietin mRNA, and the resulting overproduction of

92 is a loss-of-function variant that promotes thrombopoietin/myeloproliferative leukemia virus oncogen

93 in isolated MKs increased signaling via the thrombopoietin/myeloproliferative leukemia virus oncogen

94 megakaryocytic and erythroid progenitors by thrombopoietin or erythropoietin was unaffected.

95 When HEL cells were stimulated with thrombopoietin or phorbol 12-myristate 13-acetate (PMA),

96 2%) amplification cultures with two (Flt3L + thrombopoietin) or four cytokines (Flt3L + thrombopoieti

97 megakaryocytes in the presence or absence of thrombopoietin, or the development of megakaryocyte DNA

98 to be related to marrow injury or decreased thrombopoietin production.

99 bol-13-acetate and primary megakaryocytes by thrombopoietin promotes MKL1 nuclear localization.

100 growth factor receptor-1 (F36VFGFR1) and the thrombopoietin receptor (F36VMpl) induced a sustained ex

101 d to express a conditional derivative of the thrombopoietin receptor (F36Vmpl).

102 59457 (SB), a nonpeptidyl hydrazone class of thrombopoietin receptor (Mpl) agonist, revealed toxicity

103 5R/R938Q induced spontaneous growth of Ba/F3-thrombopoietin receptor (MPL) but not of Ba/F3-human rec

104 We have reported defective thrombopoietin receptor (Mpl) protein expression in MPD

105 Mutations of thrombopoietin, the thrombopoietin receptor (MPL), and the erythropoietin re

106 port here that amino acid substitutions in a thrombopoietin receptor (Mpl)--containing cell growth sw

107 ombopag (EP) is a small-molecule, nonpeptide thrombopoietin receptor (TPO-R) agonist that has been ap

108 ts before (n = 10) and during treatment with thrombopoietin receptor (TPO-R) agonists (n = 9).

109 Decreased expression of the thrombopoietin receptor (TPOR or MPL) on the cell surfac

110 Mutations in the MPL gene encoding the human thrombopoietin receptor (TpoR) drive sporadic and famili

111 an agonist antibody to a cytokine receptor, Thrombopoietin receptor (TPOR) that effectively induces

112 ns participate in the activity states of the thrombopoietin receptor (TpoR), a type 1 cytokine recept

113 In the human thrombopoietin receptor (TpoR), a unique amphipathic RWQ

114 l, small-molecule, nonpeptide agonist of the thrombopoietin receptor (TpoR), being developed as a tre

115 ase 2 phosphorylation, initiated through the thrombopoietin receptor (TPOR/Mpl) activation, was affec

116 ed amino acids, leading to activation of the thrombopoietin receptor (TpoR/MPL).

117 genic CALR mutants specifically activate the thrombopoietin receptor (TpoR/MPL).

118 ngle transmembrane domain (TMD) of the human thrombopoietin receptor (TpoR/myeloproliferative leukemi

119 xamine the in vivo effects of eltrombopag, a thrombopoietin receptor agonist (TPO-RA), on platelet fu

120 The thrombopoietin receptor agonist eltrombopag has been sho

121 The oral thrombopoietin receptor agonist eltrombopag is approved

122 Eltrombopag (ELT) is a thrombopoietin receptor agonist reported to decrease lab

123 The thrombopoietin receptor agonist romiplostim could be an

124 Romiplostim is a thrombopoietin receptor agonist that increases platelet

125 Eltrombopag is a small molecule thrombopoietin receptor agonist that might be a new opti

126 RE), we aimed to assess eltrombopag, an oral thrombopoietin receptor agonist, for thrombocytopenia (g

127 Eltrombopag, an oral thrombopoietin receptor agonist, increases platelet coun

128 We tested whether eltrombopag, a thrombopoietin receptor agonist, might be effective in i

129 Eltrombopag, an oral thrombopoietin receptor agonist, stimulates platelet pro

130 Thrombopoietin receptor agonists (eltrombopag; romiplost

131 has changed with the advent of rituximab and thrombopoietin receptor agonists (TPO-RAs) as options fo

132 Thrombopoietin receptor agonists (Tpo-RAs), which likely

133 efficacy and safety, in particular, for the thrombopoietin receptor agonists and the occurrence of l

134 Thrombopoietin receptor agonists are reported to increas

135 ents respond to antithymocyte globulins, and thrombopoietin receptor agonists are under investigation

136 intravenous immunoglobulin within 2 weeks or thrombopoietin receptor agonists within 4 weeks before r

137 Tier 1 options (rituximab, thrombopoietin receptor agonists, low-dose corticosteroi

138 templating pregnancy while on treatment with thrombopoietin receptor agonists, rituximab, or mycophen

139 More recently, activating mutations in the thrombopoietin receptor and in JAK2 exon 12 have been id

140 A thrombopoietin receptor derivative that brings the proli

141 atic activating mutations in JAK2 and in the thrombopoietin receptor gene (MPL) in most patients with

142 al 5 to 10% have activating mutations in the thrombopoietin receptor gene (MPL).

143 a p.Lys39Asn amino acid substitution of the thrombopoietin receptor gene (p = 1.5 x 10(-11)).

144 a chemically induced dimerizer and modified thrombopoietin receptor has now allowed the expansion of

145 mutations of the erythropoietin receptor and thrombopoietin receptor have been identified in familial

146 e discovery of an activating mutation in the thrombopoietin receptor in JAK2-negative myelofibrosis a

147 resultant mice were compared with a Mpl-/- (thrombopoietin receptor knockout) thrombocytopenic murin

148 ia a pathogenic binding interaction with the thrombopoietin receptor MPL to induce MPNs.

149 Endocytosis of the thrombopoietin receptor Mpl was impaired in Dnm2-null pl

150 e demonstrated that mutant CALR binds to the thrombopoietin receptor MPL, and that the positive elect

151 en OTT-MAL and an activating mutation of the thrombopoietin receptor myeloproliferative leukemia viru

152 miR-28 exerts negative effects on thrombopoietin receptor signaling and platelet formation

153 scribed, somatic, activating mutation in the thrombopoietin receptor that is sensitive to down-stream

154 thymic stromal lymphopoietin, eotaxin-3, and thrombopoietin receptor to the RNA-induced silencing com

155 Although the thrombopoietin receptor was discovered in 1991 and throm

156 expression of p21(Cip1), p27(Kip1), and the thrombopoietin receptor, known regulators of HSC self-re

157 nner in 1 of 3 genes: JAK2, CALR, or MPL The thrombopoietin receptor, MPL, is the key cytokine recept

158 tor, the erythropoietin receptor (EpoR), the thrombopoietin receptor, or the granulocyte colony-stimu

159 at from mice lacking c-Mpl (c-Mpl(-/-)), the thrombopoietin receptor.

160 P were randomly assigned to receive the oral thrombopoietin-receptor agonist eltrombopag (30, 50, or

161 Eltrombopag is an oral, non-peptide, thrombopoietin-receptor agonist that stimulates thrombop

162 Eltrombopag is a new, orally active thrombopoietin-receptor agonist that stimulates thrombop

163 immunosuppression, eltrombopag, a synthetic thrombopoietin-receptor agonist, led to clinically signi

164 The effects of eltrombopag, a thrombopoietin-receptor agonist, on platelet function in

165 Eltrombopag is an oral thrombopoietin-receptor agonist.

166 PURPOSE OF REVIEW: Thrombopoietin-receptor agonists (TPO-RAs) have been app

167 Stimulation of platelet production by thrombopoietin-receptor agonists (TPO-RAs) is an effecti

168 Combining an immunosuppressant therapy with thrombopoietin-receptor agonists may be a good strategy

169 combination of immunosuppressant therapy and thrombopoietin-receptor agonists that lasted for a media

170 er induction with erythropoietin, G-CSF, and thrombopoietin, respectively.

171 forms of the c-Mpl ligand--recombinant human thrombopoietin (rhTPO) and pegylated recombinant human m

172 Recombinant human thrombopoietin (rhTPO) increases platelets, and the peak

173 les exposed to SB, but not recombinant human thrombopoietin (rhTpo), in liquid suspension culture.

174 to 10 mum ABA does not increase recombinant thrombopoietin (rTpo)-dependent Mk differentiation or pl

175 nd germ-line-activating mutations affect the thrombopoietin signaling axis.

176 karyocytes to the endosteal niche depends on thrombopoietin signaling through the c-MPL receptor on m

177 ressed in hematopoietic cells and suppresses thrombopoietin signaling via its receptor myeloprolifera

178 In contrast, enhanced thrombopoietin signaling, conferred by enforced expressi

179 Treatment with recombinant human thrombopoietin significantly increased platelet count (m

180 + thrombopoietin) or four cytokines (Flt3L + thrombopoietin + stem cell factor + interleukin 3).

181 oncontact HUBEC cultures and the addition of thrombopoietin, stem cell factor (SCF), and macrophage c

182 /mpl, silencing of TRIB3 increased basal and thrombopoietin-stimulated megakaryocyte antigen expressi

183 Thrombopoietin stimulates extracellular signal-related k

184 itro to produce proplatelets, independent of thrombopoietin stimulation, and they responded to stimul

185 itself is tyrosine-phosphorylated following thrombopoietin stimulation.

186 -Mpl, the cellular receptor for the cytokine thrombopoietin, suggest that c-Mpl does not control HSC

187 tion approach, and found that high levels of thrombopoietin synergize with low levels of stem-cell fa

188 In mouse models, increased hepatic thrombopoietin synthesis in response to tumor-derived in

189 of platelet-biased HSCs crucially depends on thrombopoietin, the primary extrinsic regulator of plate

190 de, with the cloning and characterization of thrombopoietin, the primary regulator of this process.

191 Mutations of thrombopoietin, the thrombopoietin receptor (MPL), and t

192 ets collected from healthy donors undergoing thrombopoietin therapy were safe and resulted in signifi

193 The interaction between thrombopoietin (THPO) and its receptor c-Mpl regulates d

194 the hereditary thrombocytosis induced by the thrombopoietin (THPO) receptor MPL P106L mutant remain u

195 Expression of the thrombopoietin (THPO) receptor MPL was elevated in leuke

196 Thrombopoietin (Thpo) signaling through the c-Mpl recept

197 ne, MPL, a homodimeric receptor activated by thrombopoietin (THPO), is mutated in myeloproliferative

198 ealed that Bcl-xL expression is regulated by thrombopoietin (THPO)/MPL-signaling induced by AE expres

199 Thrombopoietin (Thpo)/myeloproliferative leukemia virus

200 ng identified mutations in the gene encoding thrombopoietin (THPO): THPO R99W, homozygous in affected

201 fied a novel homozygous missense mutation in thrombopoietin (THPO, c.112C>T) in both affected sibling

202 granules, and forming PPTs without exogenous thrombopoietin, thus identifying a novel and unexplored

203 althy subjects, binding of recombinant human thrombopoietin to c-Mpl induced the activation of signal

204 Finally, we administered thrombopoietin to mice beginning 5 days before marrow ra

205 The binding of thrombopoietin to Mpl activates multiple kinase pathways

206 kt in BaF3/Mpl cells restored the ability of thrombopoietin to promote cell cycling in the presence o

207 Thrombopoietin (TPO) acting via its receptor, the cellul

208 karyocyte production, signaling initiated by thrombopoietin (TPO) activation of its receptor, myelopr

209 that c-Cbl(-/-) HSCs are hyperresponsive to thrombopoietin (TPO) and display elevated levels of STAT

210 Recently, interactions between thrombopoietin (TPO) and its receptor, the myeloprolifer

211 We investigated the association of plasma thrombopoietin (TPO) and overall survival in 127 patient

212 ulxin, and the cytokine receptor Mpl agonist thrombopoietin (TPO) are able to induce activation of RA

213 Thrombopoietin (TPO) attracts much attention as an effec

214 Multiple lines of evidence indicate that thrombopoietin (TPO) contributes to the development of h

215 Here we show that thrombopoietin (TPO) cooperates with FLT3-L, inducing CD

216 In our previous studies we demonstrated that thrombopoietin (TPO) enhances levels of HOXB4 mRNA in pr

217 Thrombopoietin (TPO) enhances platelet activation throug

218 differentiated in a medium supplemented with thrombopoietin (TPO) for 18 days.

219 ition, BM from Cib1(-/-) mice, cultured with thrombopoietin (TPO) for 24 hours, produced more highly

220 vels are controlled by circulating levels of thrombopoietin (TPO) functioning to activate megakaryocy

221 etiology of this disease, we identified the thrombopoietin (Tpo) gene as a target of the SMRT-retino

222 Thrombopoietin (TPO) has been demonstrated as a crucial

223 The role of thrombopoietin (Tpo) in promoting hematopoiesis has been

224 Thrombopoietin (Tpo) is a glycoprotein growth factor tha

225 Thrombopoietin (Tpo) is the primary cytokine regulating

226 Thrombopoietin (TPO) is the primary regulator of platele

227 red thrombopoiesis leads to increased plasma thrombopoietin (TPO) levels and perturbed hematopoietic

228 is was associated with rapid upregulation of thrombopoietin (TPO) messenger RNA.

229 develop BM fibrosis upon treatment with the thrombopoietin (TPO) mimetic romiplostim (TPO(high)).

230 Finally, two thrombopoietin (Tpo) mimetics were approved by the FDA f

231 ets to the AMR induces hepatic expression of thrombopoietin (TPO) mRNA and protein, thereby regulatin

232 pffer cells, ultimately leading to increased thrombopoietin (TPO) production in the liver.

233 L), increased cell surface expression of the thrombopoietin (TPO) receptor (c-MPL) and enhanced proli

234 Here we show that loss of the thrombopoietin (TPO) receptor (MPL) significantly amelio

235 ut not CALRdelex9, specifically activate the thrombopoietin (TPO) receptor (MPL) to induce constituti

236 mbocythemia (ET) with mutations in JAK2, the thrombopoietin (TPO) receptor (MPL), and the calreticuli

237 ing through an abnormal interaction with the thrombopoietin (TPO) receptor (MPL).

238 pression of murine JAK2 V617F and the murine thrombopoietin (Tpo) receptor (TpoR, c-MPL) in hematopoi

239 The thrombopoietin (TPO) receptor c-Mpl, like other members

240 Mpl is the thrombopoietin (TPO) receptor.

241 on of these cells in the presence of dox and thrombopoietin (TPO) resulted in an exponential (at leas

242 elinexor causes thrombocytopenia by blocking thrombopoietin (TPO) signaling and therefore differentia

243 This pattern is associated with up-regulated thrombopoietin (TPO) signaling through mammalian target

244 Thrombopoietin (TPO) stimulates a network of intracellul

245 Multiple lines of evidence indicate that thrombopoietin (TPO) substantially impacts the number of

246 otein that dampens signaling by the cytokine thrombopoietin (Tpo) to limit HSC expansion.

247 The term thrombopoietin (TPO) was first coined in 1958 and used t

248 Serum thrombopoietin (TPO) was maintained at normal levels in

249 opoietin receptor was discovered in 1991 and thrombopoietin (TPO) was purified in 1994, the developme

250 design, antibody fragments (Fabs) that mimic thrombopoietin (TPO) were created.

251 IL-8, VEGF receptors VEGFR1 and VEGFR2, and thrombopoietin (TPO) were measured in plasma samples of

252 We have previously shown that thrombopoietin (TPO), a critical HSC regulator, ensures

253 mma specifically prevents full engagement of thrombopoietin (TPO), a primary positive regulator of HS

254 Thrombopoietin (Tpo), acting through its receptor c-Mpl,

255 Thrombopoietin (Tpo), acting through the c-Mpl receptor,

256 in transcription factors, in the response to thrombopoietin (Tpo), and newly described developmentall

257 Up-regulation of survivin by thrombopoietin (Tpo), Flt3 ligand (FL), and stem cell fa

258 eloproliferative leukemia), the receptor for thrombopoietin (TPO), in T cells.

259 using low levels of stem cell factor (SCF), thrombopoietin (TPO), insulin-like growth factor 2 (IGF-

260 2-step differentiation process, regulated by thrombopoietin (TPO), on binding to its cognate receptor

261 some individuals treated with a recombinant thrombopoietin (TPO), pegylated recombinant human megaka

262 ) messenger RNA (mRNA) expression; (3) serum thrombopoietin (Tpo), stem cell factor (SCF), interleuki

263 Thrombopoietin (TPO), the c-Mpl ligand, is the primary p

264 Thrombopoietin (TPO), the primary regulator of platelet

265 Thrombopoietin (TPO), the primary regulator of platelet

266 Thrombopoietin (TPO), the primary regulator of thrombopo

267 We demonstrate that in the absence of thrombopoietin (TPO), tyrosine-unphosphorylated STAT5 (u

268 one marrow endothelial cells (BMECs) promote thrombopoietin (TPO)-independent platelet production.

269 ffect of an Src kinase inhibitor, SU6656, on thrombopoietin (TPO)-induced growth and differentiation.

270 Thrombopoietin (Tpo)-induced in vitro expansion of ES ce

271 t constrains HSC expansion through dampening thrombopoietin (TPO)-induced JAK2 signaling.

272 own Lyn kinase to be a negative regulator of thrombopoietin (TPO)-induced proliferation.

273 Thrombopoietin (Tpo)-mediated activation of Lyn kinase,

274 s (HSCs) harboring DNA damage are rescued by thrombopoietin (TPO)-mediated DNA repair.1 It has been r

275 ain HSC homeostasis by positively regulating thrombopoietin (Tpo)-mediated Jak2 signaling.

276 We show that IFN-gamma reduces thrombopoietin (TPO)-mediated phosphorylation of signal

277 tion of miR-193b upon self-renewal promoting thrombopoietin (TPO)-MPL-STAT5 signalling.

278 In this study we demonstrate that thrombopoietin (TPO)-stimulated Src family kinases (SFKs

279 reaction of purified mouse MKs isolated from thrombopoietin (TPO)-treated bone marrow (BM) cultures i

280 ion signals after stimulation by its ligand, thrombopoietin (TPO).

281 adult hematopoietic microenvironment and to thrombopoietin (Tpo).

282 (CpG) demethylation that can be initiated by thrombopoietin (TPO).

283 imary mean of regulating the plasma level of thrombopoietin (TPO).

284 stromal cell derived factor-1a (SDF-1a), and thrombopoietin (TPO).

285 ting factor (GM-CSF), Steel factor (SLF), or thrombopoietin (TPO).

286 factor (SCF) + interleukin 7 (IL-7), or FL + thrombopoietin (Tpo).

287 cloned, and generated recombinant zebrafish thrombopoietin (Tpo).

288 Soluble Kit-ligand (sKitL), thrombopoietin (TPO, encoded by Thpo) and, to a lesser e

289 mbopoietic growth factors (recombinant human thrombopoietin [TPO] and pegylated recombinant human meg

290 structed by either in vivo overexpression of thrombopoietin (TPOhigh mice) or megakaryocyte lineage r

291 e 2 (JAK2) is essential for signaling by the thrombopoietin (TpoR) and erythropoietin (EpoR) receptor

292 oped with the discovery that the recombinant thrombopoietins (TPOs) could enhance platelet production

293 tion of VEGFR-3 increased platelet counts in thrombopoietin-treated mice significantly and modulated

294 giopoietin-like 3 and IGF2, but also SCF and thrombopoietin, two other growth factors important for H

295 d; and the primary regulator of the process, thrombopoietin, was cloned and characterized and therape

296 Tumor-derived interleukin-6 and hepatic thrombopoietin were also linked to thrombocytosis in pat

297 No antibodies against romiplostim or thrombopoietin were detected.

298 tibodies to either romiplostim or endogenous thrombopoietin were seen.

299 ing and have lost the potentiating effect of thrombopoietin (which couples to JAK2) on this pathway.

300 on hepatocytes to enhance the production of thrombopoietin, which in turn interacts with its cognate